Toll Free: 1-888-928-9744

Bristol-Myers Squibb Company - Product Pipeline Review - 2016

Published: Mar 30, 2016 | Pages: 255 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bristol-Myers Squibb Company - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2016', provides an overview of the Bristol-Myers Squibb Company's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Bristol-Myers Squibb Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Bristol-Myers Squibb Company
- The report provides overview of Bristol-Myers Squibb Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Bristol-Myers Squibb Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Bristol-Myers Squibb Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Bristol-Myers Squibb Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bristol-Myers Squibb Company's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Bristol-Myers Squibb Company Snapshot 7 Bristol-Myers Squibb Company Overview 7 Key Information 7 Key Facts 7 Bristol-Myers Squibb Company - Research and Development Overview 8 Key Therapeutic Areas 8 Bristol-Myers Squibb Company - Pipeline Review 18 Pipeline Products by Stage of Development 18 Pipeline Products - Monotherapy 19 Pipeline Products - Combination Treatment Modalities 20 Pipeline Products - Partnered Products 21 Pipeline Products - Out-Licensed Products 23 Bristol-Myers Squibb Company - Pipeline Products Glance 25 Bristol-Myers Squibb Company - Late Stage Pipeline Products 25 Bristol-Myers Squibb Company - Clinical Stage Pipeline Products 28 Bristol-Myers Squibb Company - Early Stage Pipeline Products 33 Bristol-Myers Squibb Company - Drug Profiles 37 nivolumab 37 daclatasvir dihydrochloride + asunaprevir 45 abatacept 47 apixaban 50 beclabuvir hydrochloride 52 brivanib alaninate 54 ipilimumab 57 ulocuplumab 62 BMS-394136 64 BMS-754807 65 BMS-833923 67 BMS-919373 69 BMS-986020 70 BMS-986036 71 BMS-986142 73 CXL-1427 74 dasatinib 75 lirilumab 78 lulizumab pegol 80 Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 81 urelumab 82 BMS-986004 84 BMS-986012 85 BMS-986016 86 BMS-986089 87 BMS-986148 88 BMS-986156 89 BMS-986158 90 TD-139 91 Antibody to Target CD40 Ligand for Immunology 93 Biologic to Inhibit PD-L1 for Immunology 94 BMS-262084 95 BMS-777607 96 BMS-813160 98 BMS-906024 99 BMS-963272 101 BMS-986090 102 BMS-986104 103 BMS-986115 104 BMS-986120 105 BMS-986141 106 BMS-986147 107 BMS-986165 108 BMS-986168 109 BMS-986171 110 BMS-986186 111 FLX-925 112 KOS-1803 113 Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 115 Small Molecule for Oncology 116 Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 117 Small Molecule to Inhibit BTK for Immunology 118 Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity 119 Small Molecule to Inhibit TYK2 for Immunology 120 BMS-817378 121 ALB-109780 122 AMR-2 123 ARX-720 125 BMS-457 126 BMS-593214 127 BMS-654457 128 BMS-751324 129 BMS-795311 130 BMS-816106 131 BMS-869780 132 BMS-871 133 BMS-884775 134 BMS-986177 135 BMS-986195 136 BMS-986205 137 CXL-1036 138 Drug for Metabolic Disorders 139 Drugs to Agonize FPR-2 for Inflammation 140 DT-1154 141 F-001287 142 NP-11948 143 Small Molecule 2 to Inhibit Factor XIa for Thrombosis 144 Small Molecule for Pulmonary Arterial Hypertension 145 Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy 146 Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity 147 Small Molecule to Antagonize NK1R and Block SERT for Depression 148 Small Molecule to Inhibit IAP for Melanoma 149 Small Molecule to Inhibit NS5B for Hepatitis C 150 Small Molecule to Inhibit XIAP and c-IAP for Melanoma 151 Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease 152 Small Molecules to Inhibit ROR-Gamma for Inflammation 153 Monoclonal Antibody Conjugates for Oncology 154 Proteins for Immunology and Oncology 155 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia 156 Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine 157 Small Molecules to Antagonize CCR2 158 Small Molecules to Inhibit IDO and TDO for Oncology 159 Small Molecules to Inhibit IDO for Oncology 160 Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases 161 Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders 162 Small Molecules to Inhibit TDO for Oncology 163 Bristol-Myers Squibb Company - Pipeline Analysis 164 Bristol-Myers Squibb Company - Pipeline Products by Target 164 Bristol-Myers Squibb Company - Pipeline Products by Route of Administration 174 Bristol-Myers Squibb Company - Pipeline Products by Molecule Type 175 Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action 176 Bristol-Myers Squibb Company - Recent Pipeline Updates 183 Bristol-Myers Squibb Company - Dormant Projects 226 Bristol-Myers Squibb Company - Dormant Projects 226 Bristol-Myers Squibb Company - Discontinued Pipeline Products 231 Bristol-Myers Squibb Company - Discontinued Pipeline Products 231 Discontinued Pipeline Product Profiles 232 Bristol-Myers Squibb Company - Company Statement 237 Bristol-Myers Squibb Company - Locations And Subsidiaries 239 Head Office 239 Other Locations & Subsidiaries 239 Bristol-Myers Squibb Company - Key Manufacturing Facilities 246 Appendix 247 Methodology 247 Coverage 247 Secondary Research 247 Primary Research 247 Expert Panel Validation 247 Contact Us 247 Disclaimer 248
List of Tables
Bristol-Myers Squibb Company, Key Information 14 Bristol-Myers Squibb Company, Key Facts 14 Bristol-Myers Squibb Company - Pipeline by Indication, 2016 16 Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016 25 Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016 26 Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016 27 Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016 28 Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016 29 Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016 30 Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016 31 Bristol-Myers Squibb Company - Pre-Registration, 2016 32 Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016 33 Bristol-Myers Squibb Company - Phase III, 2016 34 Bristol-Myers Squibb Company - Phase II, 2016 35 Bristol-Myers Squibb Company - Phase I, 2016 37 Bristol-Myers Squibb Company - IND/CTA Filed, 2016 40 Bristol-Myers Squibb Company - Preclinical, 2016 41 Bristol-Myers Squibb Company - Discovery, 2016 43 Bristol-Myers Squibb Company - Pipeline by Target, 2016 171 Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016 181 Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016 182 Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016 183 Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016 190 Bristol-Myers Squibb Company - Dormant Developmental Projects,2016 233 Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016 238 Bristol-Myers Squibb Company, Other Locations 246 Bristol-Myers Squibb Company, Subsidiaries 246 Bristol-Myers Squibb Company, Key Manufacturing Facilities 253


List of Figures
Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016 16 Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016 25 Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016 26 Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016 27 Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016 28 Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016 30 Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016 171 Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016 181 Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016 182 Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016 183

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify